$9.59
2.34% day before yesterday
Nasdaq, Jul 11, 10:15 pm CET
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Syndax Pharmaceuticals Inc Stock price

$9.59
-1.31 12.02% 1M
-3.21 25.08% 6M
-3.63 27.46% YTD
-13.91 59.19% 1Y
-8.92 48.19% 3Y
-4.80 33.36% 5Y
-2.42 20.15% 10Y
-2.42 20.15% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.23 2.34%
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Key metrics

Basic
Market capitalization
$825.2m
Enterprise Value
$654.1m
Net debt
positive
Cash
$516.3m
Shares outstanding
86.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
18.9 | 6.6
EV/Sales
15.0 | 5.2
EV/FCF
negative
P/B
3.8
Financial Health
Equity Ratio
39.8%
Return on Equity
-110.6%
ROCE
-62.9%
ROIC
-356.7%
Debt/Equity
1.6
Financials (TTM | estimate)
Revenue
$43.7m | $125.8m
EBITDA
$-343.7m | $-353.0m
EBIT
$-343.7m | $-344.6m
Net Income
$-331.2m | $-338.9m
Free Cash Flow
$-286.5m
Growth (TTM | estimate)
Revenue
- | 431.1%
EBITDA
-30.4% | -3.9%
EBIT
-30.4% | -1.4%
Net Income
-37.7% | -6.3%
Free Cash Flow
-39.8%
Margin (TTM | estimate)
Gross
59.5%
EBITDA
-786.0% | -280.7%
EBIT
-786.0%
Net
-757.5% | -269.5%
Free Cash Flow
-655.3%
More
EPS
$-3.9
FCF per Share
$-3.3
Short interest
28.9%
Employees
270
Rev per Employee
$90.0k
Show more

Is Syndax Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Syndax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

17x Buy
89%
2x Hold
11%

Analyst Opinions

19 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

Buy
89%
Hold
11%

Financial data from Syndax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
44 44
-
100%
- Direct Costs 1.71 1.71
-
4%
26 26
-
59%
- Selling and Administrative Expenses 139 139
78% 78%
318%
- Research and Development Expense 247 247
33% 33%
564%
-344 -344
30% 30%
-786%
- Depreciation and Amortization 0.01 0.01
50% 50%
0%
EBIT (Operating Income) EBIT -344 -344
30% 30%
-786%
Net Profit -331 -331
38% 38%
-758%

In millions USD.

Don't miss a Thing! We will send you all news about Syndax Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Syndax Pharmaceuticals Inc Stock News

Neutral
Seeking Alpha
5 days ago
Syndax now has two approved therapies—NIKTIMVO and Revuforj—but the share price remains under pressure despite these milestones. NIKTIMVO faces a crowded cGVHD market and skepticism about its commercial potential, with analysts projecting modest long-term sales. Revuforj offers significant upside, targeting an underserved leukemia niche with minimal competition and potential for label expansion...
Neutral
GlobeNewsWire
10 days ago
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2025 the Company granted inducement awards to purchase up to 228,400 shares of common stock to 14 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years,...
Neutral
GlobeNewsWire
18 days ago
– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA's RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar acute leukemia – NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapi...
More Syndax Pharmaceuticals Inc News

Company Profile

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Metzger
Employees 270
Founded 2005
Website syndax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today